Ohhashi S - Search Results

1

Twist, a novel oncogene, is upregulated in pancreatic cancer: clinical implication of Twist expression in pancreatic juice.

Ohuchida K, Mizumoto K, Ohhashi S, Yamaguchi H, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M. Ohuchida K, et al. Among authors: ohhashi s. Int J Cancer. 2007 Apr 15;120(8):1634-40. doi: 10.1002/ijc.22295. Int J Cancer. 2007. PMID: 17236203

2

S100A11, a putative tumor suppressor gene, is overexpressed in pancreatic carcinogenesis.

Ohuchida K, Mizumoto K, Ohhashi S, Yamaguchi H, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M. Ohuchida K, et al. Among authors: ohhashi s. Clin Cancer Res. 2006 Sep 15;12(18):5417-22. doi: 10.1158/1078-0432.CCR-06-0222. Clin Cancer Res. 2006. PMID: 17000675

3

Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer.

Yamada D, Ohuchida K, Mizumoto K, Ohhashi S, Yu J, Egami T, Fujita H, Nagai E, Tanaka M. Yamada D, et al. Among authors: ohhashi s. Anticancer Res. 2007 Mar-Apr;27(2):793-9. Anticancer Res. 2007. PMID: 17465204 Free article.

4

Midkine mRNA is overexpressed in pancreatic cancer.

Ohhashi S, Ohuchida K, Mizumoto K, Egami T, Yu J, Cui L, Toma H, Takahata S, Nabae T, Tanaka M. Ohhashi S, et al. Dig Dis Sci. 2009 Apr;54(4):811-5. doi: 10.1007/s10620-008-0434-4. Epub 2008 Aug 21. Dig Dis Sci. 2009. PMID: 18712601

5

Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.

Ohhashi S, Ohuchida K, Mizumoto K, Fujita H, Egami T, Yu J, Toma H, Sadatomi S, Nagai E, Tanaka M. Ohhashi S, et al. Anticancer Res. 2008 Jul-Aug;28(4B):2205-12. Anticancer Res. 2008. PMID: 18751396 Free article.

6

The endoscopic intratumor administration of OK-432 in gastric cancer unsuitable for surgery.

Nakazawa S, Yoshino J, Kijima Y, Yasumasa N, Ohhashi S, Mizutani K. Nakazawa S, et al. Among authors: ohhashi s. Endoscopy. 1989 Jul;21(4):168-71. doi: 10.1055/s-2007-1012934. Endoscopy. 1989. PMID: 2776702

7

Altered renal response to enhanced endogenous 5-hydroxytryptamine after tryptophan administration in essential hypertension.

Tomoda F, Takata M, Oh-Hashi S, Ueno H, Yasumoto K, Iida H, Sasayama S. Tomoda F, et al. Clin Sci (Lond). 1992 May;82(5):551-7. doi: 10.1042/cs0820551. Clin Sci (Lond). 1992. PMID: 1317765 Clinical Trial.

8

Time course of regression of vascular structural changes and its relation to cytosolic free calcium in hypertensives after nilvadipine treatment.

Ueno H, Takata M, Oh-hashi S, Tomoda F, Yasumoto K, Inoue H. Ueno H, et al. J Hum Hypertens. 1995 Sep;9(9):735-9. J Hum Hypertens. 1995. PMID: 8551487 Clinical Trial.

9

Regression of vascular structural changes and calcium metabolism in patients with essential hypertension after long-term monotherapy with enalapril.

Ueno H, Takata M, Oh-hashi S, Tomoda F, Yasumoto K, Iida H, Sasayama S. Ueno H, et al. J Hum Hypertens. 1993 Apr;7(2):125-30. J Hum Hypertens. 1993. PMID: 8510084

10

Cytosolic free calcium concentration in platelets in patients with renovascular hypertension and primary aldosteronism.

Oh-hashi S, Takata M, Ueno H, Tomoda F, Yasumoto K, Iida H, Sasayama S. Oh-hashi S, et al. J Hum Hypertens. 1992 Feb;6(1):71-4. J Hum Hypertens. 1992. PMID: 1583634

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters